Innate Pharma S.A. (IPHA) Stock Forecast
IPHA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $6.67 average of analyst targets
- Upside to target
- +366.2% from the latest close
- Next earnings
- —
- 52-week range
- $1.17 – $2.54
IPHA analyst ratings
3 analystsNumber of analysts at each rating.
IPHA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IPHA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.15 | — | — | 1 |
| Current fiscal year (2026) | −$0.18 | −$0.53 | $0.16 | −$0.64 | +71.2% | 2 |
| Next fiscal year (2027) | −$0.47 | −$0.50 | −$0.45 | −$0.18 | −156.9% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IPHA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.3M | $2.3M | $2.3M | — | 1 |
| Current fiscal year (2026) | $44.2M | $8.2M | $84.3M | +390.6% | 4 |
| Next fiscal year (2027) | $107.4M | $10.2M | $267.0M | +143.1% | 4 |
IPHA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IPHA revenue: reported and forecast
IPHA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.07 | −$0.07 | −$0.07 | −$0.15 | +8.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.55 | −$0.55 | −$0.09 | −$0.28 | −$0.18 | −66.5% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.63 | −$0.63 | −$0.63 | −$0.59 | −$0.47 | −25.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IPHA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IPHA beat in 10 of 11.
What analysts expect from IPHA
3 analysts cover Innate Pharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.67, 366.2% above the latest close of $1.43. Analysts expect earnings of −$0.18 per share for 2026, +71.2% from a year earlier. For 2027 the average estimate is −$0.47 per share on revenue of $107.4 million. Innate Pharma beat the EPS estimate in 10 of the last 11 quarters.
Related: IPHA income statement, IPHA key metrics, IPHA chart. See the IPHA stock overview for the latest quote and news.
IPHA forecast FAQ
What is Innate Pharma's price target?
The average analyst price target for Innate Pharma is $6.67, 366.2% above the latest close of $1.43.
Is Innate Pharma a buy, hold or sell?
Of 3 analysts covering Innate Pharma, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Innate Pharma's EPS forecast?
Analysts forecast −$0.18 per share for 2026 (range −$0.53 to $0.16); for 2027 the estimate is −$0.47.
What is Innate Pharma's revenue forecast?
The average revenue estimate for 2026 is $44.2 million, growth of 390.6%; for 2027 it is $107.4 million.
Does Innate Pharma usually beat earnings estimates?
Innate Pharma reported EPS at or above the analyst estimate in 10 of the last 11 quarters.